{"PubmedArticle": [{"MedlineCitation": {"SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "OtherAbstract": [], "CitationSubset": ["IM"], "KeywordList": [], "GeneralNote": [], "PMID": "10856454", "DateCompleted": {"Year": "2000", "Month": "08", "Day": "10"}, "DateRevised": {"Year": "2019", "Month": "06", "Day": "24"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": [], "Journal": {"ISSN": "0014-2999", "JournalIssue": {"Volume": "398", "Issue": "1", "PubDate": {"Year": "2000", "Month": "Jun", "Day": "09"}}, "Title": "European journal of pharmacology", "ISOAbbreviation": "Eur J Pharmacol"}, "ArticleTitle": "Antiarrhythmic and cardiohemodynamic effects of a novel Ca(2+) channel blocker, AH-1058, assessed in canine arrhythmia models.", "Pagination": {"StartPage": "107", "EndPage": "112", "MedlinePgn": "107-12"}, "Abstract": {"AbstractText": ["The antiarrhythmic profile and cardiohemodynamic effect of a novel Ca(2+) channel blocker, 4-(5H-Dibenzo[a, d]cyclohepten-5-ylidene)-1-[(E)-3-(3-methoxy-2-nitro)phenyl-2-p ropeny l]piperidine hydrochloride (AH-1058), were analyzed using the epinephrine-, digitalis- and two-stage coronary ligation-induced canine ventricular arrhythmia models. Intravenous administration of AH-1058 (100 microg/kg) effectively suppressed each of the ventricular arrhythmias accompanied by weak hypotensive effects. The results contrast well with those of a typical Ca(2+) channel blocker, verapamil, which suppresses only the epinephrine-induced ventricular arrhythmia with severe hypotension. These results indicate that AH-1058 may possess a more selective inhibitory action on Ca(2+) channels in the heart than on those in the vessels. Furthermore, the antiarrhythmic actions of AH-1058 were slower in onset and longer-lasting, than those in our previous studies using other antiarrhythmic drugs, including Na(+) and Ca(2+) channel blockers. The antiarrhythmic effects of AH-1058 did not correlate with its plasma concentrations when administered either intravenously or orally. These results suggest that AH-1058 can become a long-acting Ca(2+) channel blocker with unique antiarrhythmic properties, and that AH-1058 may be used in certain pathological processes, for which selective inhibition of the cardiac Ca(2+) channels is essential."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Research Laboratories, Ajinomoto Co., Inc., 1-1 Suzuki-Cho, Kawasaki-Ku, 210-8681, Kawasaki, Japan. akira_takahara@ajinomoto.com"}], "Identifier": [], "LastName": "Takahara", "ForeName": "A", "Initials": "A"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Sugiyama", "ForeName": "A", "Initials": "A"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Dohmoto", "ForeName": "H", "Initials": "H"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Yoshimoto", "ForeName": "R", "Initials": "R"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Hashimoto", "ForeName": "K", "Initials": "K"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Netherlands", "MedlineTA": "Eur J Pharmacol", "NlmUniqueID": "1254354", "ISSNLinking": "0014-2999"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Anti-Arrhythmia Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Bridged Bicyclo Compounds"}, {"RegistryNumber": "0", "NameOfSubstance": "Calcium Channel Blockers"}, {"RegistryNumber": "0", "NameOfSubstance": "Cardiovascular Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Piperidines"}, {"RegistryNumber": "YKH834O4BH", "NameOfSubstance": "Epinephrine"}, {"RegistryNumber": "Z3XPW9JWMU", "NameOfSubstance": "AH 1058"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Anti-Arrhythmia Agents"}, {"QualifierName": ["chemically induced", "physiopathology", "prevention & control"], "DescriptorName": "Arrhythmias, Cardiac"}, {"QualifierName": ["blood", "pharmacology"], "DescriptorName": "Bridged Bicyclo Compounds"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Calcium Channel Blockers"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Cardiovascular Agents"}, {"QualifierName": ["surgery"], "DescriptorName": "Coronary Vessels"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Digitalis"}, {"QualifierName": [], "DescriptorName": "Disease Models, Animal"}, {"QualifierName": [], "DescriptorName": "Dogs"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Epinephrine"}, {"QualifierName": [], "DescriptorName": "Ligation"}, {"QualifierName": ["blood", "pharmacology"], "DescriptorName": "Piperidines"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": [], "DescriptorName": "Plants, Toxic"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2000", "Month": "6", "Day": "17", "Hour": "9", "Minute": "0"}, {"Year": "2000", "Month": "8", "Day": "12", "Hour": "11", "Minute": "0"}, {"Year": "2000", "Month": "6", "Day": "17", "Hour": "9", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["10856454", "10.1016/s0014-2999(00)00293-4", "S0014-2999(00)00293-4"]}}], "PubmedBookArticle": []}